Methods of treatment using anti-IL-17F antibodies
This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
1. A method of treating an autoimmune disease or inflammatory disorder, the method comprising administering an effective amount of an anti-IL-17F antibody, or an antigen-binding fragment thereof, to a subject in need thereof, wherein said antibody, or antigen-binding fragment thereof, comprises:
(a) a V H CDR1 region comprising the amino acid sequence of SEQ ID NO: 45;
(b) a V H CDR2 region comprising the amino acid sequence of SEQ ID NO: 46;
(c) a V H CDR3 region comprising the amino acid sequence of SEQ ID NO: 47;
(d) a V L CDR1 region comprising the amino acid sequence of SEQ ID NO: 74;
(e) a V L CDR2 region comprising the amino acid sequence of SEQ ID NO: 75; and
(f) a V L CDR3 region comprising the amino acid sequence of SEQ ID NO: 76.
2. The method of claim 1 , wherein said subject is a human.
3. A method of treating rheumatoid arthritis, Crohn's disease, psoriasis, multiple sclerosis, chronic obstructive pulmonary disease, ulcerative colitis or asthma in a subject, the method comprising administering an effective amount of an antagonist of IL-17F to a subject in need thereof, wherein said antagonist comprises a monoclonal anti-IL-17F antibody, or an antigen-binding fragment thereof, comprising:
(a) a V H CDR1 region comprising the amino acid sequence of SEQ ID NO: 45;
(b) a V H CDR2 region comprising the amino acid sequence of SEQ ID NO: 46;
(c) a V H CDR3 region comprising the amino acid sequence of SEQ ID NO: 47;
(d) a V L CDR1 region comprising the amino acid sequence of SEQ ID NO: 74;
(e) a V L CDR2 region comprising the amino acid sequence of SEQ ID NO: 75; and
(f) a V L CDR3 region comprising the amino acid sequence of SEQ ID NO: 76.
4. The method of claim 3 , wherein said antibody comprises a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 10, and a light chain variable sequence comprising the amino acid sequence of SEQ ID NO: 12 or 103.
5. The method of claim 3 , wherein said subject is a human.
6. A method of treating, ameliorating, or delaying the progression of an inflammatory arthritic condition, the method comprising administering an effective amount of an anti-IL-17F antibody, or an antigen-binding fragment thereof, to a subject in need thereof, wherein said antibody, or antigen-binding fragment thereof, comprises:
(a) a V H CDR1 region comprising the amino acid sequence of SEQ ID NO: 45;
(b) a V H CDR2 region comprising the amino acid sequence of SEQ ID NO: 46;
(c) a V H CDR3 region comprising the amino acid sequence of SEQ ID NO: 47;
(d) a V L CDR1 region comprising the amino acid sequence of SEQ ID NO: 74;
(e) a V L CDR2 region comprising the amino acid sequence of SEQ ID NO: 75; and
(f) a V L CDR3 region comprising the amino acid sequence of SEQ ID NO: 76.
7. The method of claim 6 , wherein said subject is a human.
8. The method of claim 6 , wherein the arthritic condition is an autoimmune arthritic condition.
9. The method of claim 6 , wherein the inflammatory arthritic condition is rheumatoid arthritis.
10. The method of claim 3 , 1 , or 6 , wherein said antibody is an IgG isotype.
11. The method of claim 10 , wherein said antibody is an IgG1 isotype.
12. The method of claim 3 , 1 , or 6 , wherein said antibody does not bind the IL-17A homodimer.